Telix Pharmaceuticals is lauding updated guidelines from medical societies that include its investigational PET agent, TLX250-CDx (Zircaix, Zr-DFO-girentuximab-89), for molecular imaging of renal masses.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM), and the American College of Nuclear Medicine (ACNM) have included the agent in their respective guidelines.
This recognition will raise awareness about Zircaix's potential in effective renal imaging for lesion characterization and treatment guidance, according to the firm.
Telix’s phase III ZIRCON trial showed that the PET agent achieved high sensitivity, specificity, and positive predictive value for imaging clear cell renal cell carcinoma (ccRCC). Zircaix works by binding to carbonic anhydrase IX (CAIX), a target protein expressed in most ccRCC cells. This helps to produce images with high tumor-to-background ratio and high intra- and interreader consistency, the company noted.
